Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.

Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR.

Int J Med Sci. 2019 Jun 10;16(7):1018-1022. doi: 10.7150/ijms.34141. eCollection 2019.

2.

Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis.

Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, Matok I.

Drug Saf. 2019 Apr;42(4):529-538. doi: 10.1007/s40264-018-0751-2.

PMID:
30368737
3.

Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review.

Khan F, Ismail M, Khan Q, Ali Z.

Expert Opin Drug Saf. 2018 Oct;17(10):1029-1039. doi: 10.1080/14740338.2018.1520837. Epub 2018 Sep 17. Review.

PMID:
30193085
4.

Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.

Patel N, Hatley O, Berg A, Romero K, Wisniowska B, Hanna D, Hermann D, Polak S.

AAPS J. 2018 Mar 14;20(3):47. doi: 10.1208/s12248-018-0199-4.

PMID:
29541956
5.

Drug-induced QT Interval Prolongation in the Intensive Care Unit.

Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G.

Curr Clin Pharmacol. 2017;12(4):210-222. doi: 10.2174/1574884713666180223123947. Review.

PMID:
29473523
6.

Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis.

Lehmann DF, Eggleston WD, Wang D.

Pharmacotherapy. 2018 Mar;38(3):341-348. doi: 10.1002/phar.2087. Epub 2018 Feb 19.

PMID:
29380488
7.

Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.

Ellermann C, Sterneberg M, Kochhäuser S, Dechering DG, Fehr M, Eckardt L, Frommeyer G.

Europace. 2018 Oct 1;20(10):1699-1706. doi: 10.1093/europace/eux383.

PMID:
29377987
8.

Emergency department approach to QTc prolongation.

Pourmand A, Mazer-Amirshahi M, Chistov S, Sabha Y, Vukomanovic D, Almulhim M.

Am J Emerg Med. 2017 Dec;35(12):1928-1933. doi: 10.1016/j.ajem.2017.08.044. Epub 2017 Aug 24. Review.

PMID:
28855066
9.

The anaesthetized rabbit with acute atrioventricular block provides a new model for detecting drug-induced Torsade de Pointes.

Hagiwara M, Shibuta S, Takada K, Kambayashi R, Nakajo M, Aimoto M, Nagasawa Y, Takahara A.

Br J Pharmacol. 2017 Aug;174(15):2591-2605. doi: 10.1111/bph.13870. Epub 2017 Jul 5.

10.

Antimicrobials and QT prolongation.

Mason JW.

J Antimicrob Chemother. 2017 May 1;72(5):1272-1274. doi: 10.1093/jac/dkw591.

PMID:
28160473
11.

Is cardiovascular risk a concern when prescribing azithromycin?

Sutton SS.

JAAPA. 2017 Jan;30(1):11-13. doi: 10.1097/01.JAA.0000511033.34198.95.

PMID:
28033168
12.

Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.

Jackobson G, Carmel NN, Lotan D, Kremer A, Justo D.

Z Gerontol Geriatr. 2018 Jan;51(1):41-47. doi: 10.1007/s00391-016-1155-5. Epub 2016 Nov 22. Review.

PMID:
27878411
13.

Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study.

Flanagan S, Litwin J, Fang E, Prokocimer P.

Int J Antimicrob Agents. 2016 Jul;48(1):33-40. doi: 10.1016/j.ijantimicag.2015.12.015. Epub 2016 Jun 2.

PMID:
27342387
14.

Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.

Tisdale JE.

Can Pharm J (Ott). 2016 May;149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 8. Review.

15.

Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation.

Niedrig D, Maechler S, Hoppe L, Corti N, Kovari H, Russmann S.

Eur J Clin Pharmacol. 2016 Jul;72(7):859-67. doi: 10.1007/s00228-016-2043-z. Epub 2016 Mar 29.

PMID:
27023463
16.

Impaired Inactivation of L-Type Ca2+ Current as a Potential Mechanism for Variable Arrhythmogenic Liability of HERG K+ Channel Blocking Drugs.

Kim JG, Sung DJ, Kim HJ, Park SW, Won KJ, Kim B, Shin HC, Kim KS, Leem CH, Zhang YH, Cho H, Bae YM.

PLoS One. 2016 Mar 1;11(3):e0149198. doi: 10.1371/journal.pone.0149198. eCollection 2016.

17.

Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.

Marostica E, Van Ammel K, Teisman A, Boussery K, Van Bocxlaer J, De Ridder F, Gallacher D, Vermeulen A.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):659-79. doi: 10.1007/s10928-015-9434-0. Epub 2015 Aug 11.

PMID:
26259721
18.

Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect.

Salimi A, Eybagi S, Seydi E, Naserzadeh P, Kazerouni NP, Pourahmad J.

Xenobiotica. 2016;46(1):82-93. doi: 10.3109/00498254.2015.1046975. Epub 2015 Jun 11.

PMID:
26068526
19.

Weighing the adverse cardiac effects of fluoroquinolones: A risk perspective.

Mehrzad R, Barza M.

J Clin Pharmacol. 2015 Nov;55(11):1198-206. doi: 10.1002/jcph.553. Epub 2015 Aug 18. Review.

PMID:
26011799
20.

Cardiac arrest and electrical storm due to recurrent torsades de pointes caused by concomitant clarithromycin, cotrimoxazole and amiodarone treatment.

Bienias P, Ciurzyński M, Paczyńska M, Pruszczyk P.

Pol Merkur Lekarski. 2014 Nov;37(221):285-8.

PMID:
25546990

Supplemental Content

Loading ...
Support Center